#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14476	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2312	766.5	0	.	n	.	0	A69G	SNP	69	69	A	439	439	G	977	G,A,C	734,238,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14476	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2312	766.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1820	1820	T	936	T,C	932,4	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14476	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2312	766.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1554	1554	C	994	C,T	993,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24428	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3985	763.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1880	1880	A	994	A,T	993,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24428	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3985	763.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2514	2514	C	895	C,T	893,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24428	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3985	763.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2588	2588	A	888	A,G	887,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24428	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3985	763.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3140	3140	C	880	C,A	879,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	2260	folP	852	852	99.88	folP.l15.c4.ctg.1	2075	135.8	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1108	1110	AAA	219;217;217	A;A,C;A,G,C	219;216,1;215,1,1	.	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	539	2260	folP	852	852	99.88	folP.l15.c4.ctg.1	2075	135.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1339	1341	AGC	246;244;244	A;G;C	246;244;244	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5576	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3853	180.4	1	SNP	p	S91F	0	.	.	271	273	TCC	789	791	TCC	200;199;197	T,C;C;C	199,1;199;197	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5576	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3853	180.4	1	SNP	p	D95G	0	.	.	283	285	GAC	801	803	GAC	207;208;205	G,C;A,C;C	206,1;207,1;205	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5576	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3853	180.4	1	SNP	p	D95N	0	.	.	283	285	GAC	801	803	GAC	207;208;205	G,C;A,C;C	206,1;207,1;205	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1906	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1776	133.9	1	SNP	p	G45D	0	.	.	133	135	GGC	702	704	GGC	230;229;230	G;G,A;C	230;228,1;230	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1056	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1471	89.5	0	.	n	.	0	A197.	DEL	197	197	A	801	801	A	226	A	226	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4968	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3549	174.3	1	SNP	p	D86N	0	.	.	256	258	GAC	876	878	GAC	224;228;226	G;A;C	224;228;226	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4968	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3549	174.3	1	SNP	p	S87I	0	.	.	259	261	AGT	879	881	AGT	225;227;224	A;G;T,G	225;227;223,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4968	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3549	174.3	1	SNP	p	S87R	0	.	.	259	261	AGT	879	881	AGT	225;227;224	A;G;T,G	225;227;223,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4968	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3549	174.3	1	SNP	p	S87W	0	.	.	259	261	AGT	879	881	AGT	225;227;224	A;G;T,G	225;227;223,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4968	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3549	174.3	1	SNP	p	S88P	0	.	.	262	264	TCC	882	884	TCC	224;224;227	T,G,A;C;C,A	222,1,1;224;226,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4422	parE	1986	1986	100.0	parE.l6.c30.ctg.1	3110	177.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1777	1779	GGC	243;244;245	G,C;G;C	242,1;244;245	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2918	166.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1546	1548	GCA	233;235;236	G;C;A,C,G	233;235;233,2,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2918	166.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1549	1551	ATC	235;234;237	A;T;C,T	235;234;236,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2918	166.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1561	1563	GTG	242;245;244	G,T;T,G;G	240,1;244,1;244	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2918	166.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1561	1563	GTG	242;245;244	G,T;T,G;G	240,1;244,1;244	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2918	166.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2065	2067	ACC	220;218;220	A,T;C,T;C	218,1;216,1;219	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2918	166.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2119	2121	GCG	223;220;222	G,T;C;G	222,1;220;222	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2918	166.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2119	2121	GCG	223;220;222	G,T;C;G	222,1;220;222	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2918	166.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2242	2244	GGC	212;214;213	G,T;G;C	211,1;214;213	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2918	166.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2251	2253	GGC	219;223;223	G;G;C,A	219;223;222,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3890	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2918	166.1	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2269	2271	CTG	241;238;238	C,A;T;G	240,1;238;238	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5338	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3544	187.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1835	1837	CCG	208;208;208	C;C,A;G	208;207,1;208	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2398	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2206	135.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	775	775	C	201	C	201	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	V258L	NONSYN	772	774	GTA	13	15	TTA	21;23;24	T;T;A	21;23;24	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	58	60	CAT	58;58;58	C;A;T	58;58;58	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	D274S	NONSYN	820	822	GAT	61	63	AGT	58;58;58	A;G;T	58;58;58	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	70	72	TAC	58;58;58	T,A;A;C	57,1;58;58	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	R307A	NONSYN	919	921	AGA	160	162	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	T311A	NONSYN	931	933	ACA	172	174	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	E312D	NONSYN	934	936	GAA	175	177	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	F314I	NONSYN	940	942	TTC	181	183	ATC	1;1;1	A;T;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	A316S	NONSYN	946	948	GCG	187	189	TCG	1;1;1	T;C;G	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	V318A	NONSYN	952	954	GTC	193	195	GCC	1;1;1	G;C;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	G319S	NONSYN	955	957	GGC	196	198	AGC	1;1;1	A;G;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	G320A	NONSYN	958	960	GGT	199	201	GCC	1;1;1	G;C;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	222	90.54	porB1a.l15.c4.ctg.1	371	27.2	0	.	p	.	0	G322V	NONSYN	964	966	GGT	205	207	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	100	95.0	porB1a.l15.c4.ctg.2	182	41.9	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	48;45;43	A;C;G	48;45;43	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	248	porB1a	984	100	95.0	porB1a.l15.c4.ctg.2	182	41.9	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	12;11;11	C;A;A	12;11;11	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1644	197.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	539	541	GAA	245;244;239	G;A;A	245;244;239	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1644	197.8	0	.	p	.	0	N134D	NONSYN	400	402	AAT	827	829	GAT	219;219;219	G;A,G;T	219;218,1;219	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1644	197.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	950	952	TCA	258;257;257	T;C,G;A,T,C	258;256,1;255,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1644	197.8	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1079	1081	GTC	220;220;218	G,C;T;C	219,1;220;218	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1644	197.8	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1091	1093	TCT	210;211;211	T,A,G;C,G,A;T,A	208,1,1;208,2,1;210,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1644	197.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1409	1411	GCA	236;238;237	G;C;A	236;238;237	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1644	197.8	1	SNP	p	G120K	1	.	.	358	360	AAG	785	787	AAG	222;222;222	A;A;G	222;222;222	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1644	197.8	1	SNP	p	A121D	1	.	.	361	363	GAC	788	790	GAC	220;217;215	G;A,G;C,A	220;216,1;214,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2672	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1644	197.8	1	SNP	p	D121N	0	.	.	361	363	GAC	788	790	GAC	220;217;215	G;A,G;C,A	220;216,1;214,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9366	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5251	222.2	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2204	2206	AAT	256;255;255	A;A;T	254;254;255	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1370	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1446	118.2	1	SNP	p	V57M	1	.	.	169	171	ATG	712	714	ATG	265;266;265	A;T;G	265;266;265	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
